CASI Pharmaceuticals Inc

CASI Pharmaceuticals, Inc. is a biopharmaceutical company that develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. Its product EVOMELA is an intravenous formulation of melphalan used as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. Its hematology/oncology pipeline includes CNCT19, an autologous CD19 CAR-T investigative product; BI-1206, an anti-Fc"RIIB antibody for solid tumors and relapsed/refractory non-Hodgkin lymphoma; CB-5339, a VCP/p97 inhibitor; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent with various indications, including conditioning prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd., BioInvent International AB, Black Belt Therapeutics Limited, Cleave Therapeutics, Inc., and Acrotech Biopharma L.L.C. to develop and commercialize EVOMELA. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.